262 related articles for article (PubMed ID: 8053154)
21. Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2.
Eisenberg RJ; Ponce de Leon M; Friedman HM; Fries LF; Frank MM; Hastings JC; Cohen GH
Microb Pathog; 1987 Dec; 3(6):423-35. PubMed ID: 2849025
[TBL] [Abstract][Full Text] [Related]
22. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
Whaley K; Schur PH; Ruddy S
J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
[TBL] [Abstract][Full Text] [Related]
23. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
[TBL] [Abstract][Full Text] [Related]
24. Induction of granulocyte histaminase release by particle-bound complement C3 cleavage products (C3b, C3bi) and IgG.
Melamed J; Medicus RG; Arnaout MA; Colten HR
J Immunol; 1983 Jul; 131(1):439-44. PubMed ID: 6223078
[TBL] [Abstract][Full Text] [Related]
25. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
Pangburn MK; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
[TBL] [Abstract][Full Text] [Related]
26. Neomycin inhibits glycoprotein C (gC)-dependent binding of herpes simplex virus type 1 to cells and also inhibits postbinding events in entry.
Herold BC; Spear PG
Virology; 1994 Aug; 203(1):166-71. PubMed ID: 8030274
[TBL] [Abstract][Full Text] [Related]
27. Identification of C3b-binding regions on herpes simplex virus type 2 glycoprotein C.
Seidel-Dugan C; Ponce de Leon M; Friedman HM; Eisenberg RJ; Cohen GH
J Virol; 1990 May; 64(5):1897-906. PubMed ID: 2157859
[TBL] [Abstract][Full Text] [Related]
28. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity.
McNearney TA; Odell C; Holers VM; Spear PG; Atkinson JP
J Exp Med; 1987 Nov; 166(5):1525-35. PubMed ID: 2824652
[TBL] [Abstract][Full Text] [Related]
29. Direct binding of herpes simplex virus type 1 virions to complement C3.
Chen YT; Wang YH; Cheng YY; Hung SL
Viral Immunol; 2003; 16(3):347-55. PubMed ID: 14583149
[TBL] [Abstract][Full Text] [Related]
30. Pathogenic potentials of glycoprotein C-negative syncytial mutants from rabbit T cells infected persistently with herpes simplex virus type 1.
Ishida Y; Okabe T; Azukizawa Y; Isono T; Seto A
J Med Virol; 2005 May; 76(1):89-97. PubMed ID: 15779044
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
[TBL] [Abstract][Full Text] [Related]
32. Binding of complement component C3b to glycoprotein gC of herpes simplex virus type 1: mapping of gC-binding sites and demonstration of conserved C3b binding in low-passage clinical isolates.
Friedman HM; Glorioso JC; Cohen GH; Hastings JC; Harris SL; Eisenberg RJ
J Virol; 1986 Nov; 60(2):470-5. PubMed ID: 3021981
[TBL] [Abstract][Full Text] [Related]
33. Herpes simplex virus type 1 infection of endothelial, epithelial, and fibroblast cells induces a receptor for C3b.
Smiley ML; Hoxie JA; Friedman HM
J Immunol; 1985 Apr; 134(4):2673-8. PubMed ID: 2982950
[TBL] [Abstract][Full Text] [Related]
34. Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.
Mold C; Bradt BM; Nemerow GR; Cooper NR
J Immunol; 1988 Jun; 140(11):3867-74. PubMed ID: 2836501
[TBL] [Abstract][Full Text] [Related]
35. Characterization of glycoprotein C of HSZP strain of herpes simplex virus 1.
Oravcová I; Kúdelová M; Mlcuchová J; Matis J; Bystrická M; Westra DF; Welling-Wester S; Rajcáni J
Acta Virol; 2000 Apr; 44(2):99-108. PubMed ID: 10989701
[TBL] [Abstract][Full Text] [Related]
36. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
Fearon DT; Austen KF
J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
[TBL] [Abstract][Full Text] [Related]
37. Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules.
Tal-Singer R; Peng C; Ponce De Leon M; Abrams WR; Banfield BW; Tufaro F; Cohen GH; Eisenberg RJ
J Virol; 1995 Jul; 69(7):4471-83. PubMed ID: 7769707
[TBL] [Abstract][Full Text] [Related]
38. Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose.
Vogt W; Schmidt G; Dieminger L; Lynen R
Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(5):440-55. PubMed ID: 126576
[TBL] [Abstract][Full Text] [Related]
39. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC.
Lubinski J; Wang L; Mastellos D; Sahu A; Lambris JD; Friedman HM
J Exp Med; 1999 Dec; 190(11):1637-46. PubMed ID: 10587354
[TBL] [Abstract][Full Text] [Related]
40. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC.
Friedman HM; Wang L; Fishman NO; Lambris JD; Eisenberg RJ; Cohen GH; Lubinski J
J Virol; 1996 Jul; 70(7):4253-60. PubMed ID: 8676446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
